Frespaciguat
Sponsors
Merck Sharp & Dohme LLC
Conditions
Chronic Obstructive Pulmonary DiseaseCoronavirus Disease 2019 (COVID-19)Hypertension, PulmonaryHypoxemiaPneumoniaPulmonary Arterial HypertensionPulmonary Hypertension
Phase 1
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
CompletedNCT03744637
Start: 2019-01-18End: 2020-12-11Updated: 2025-06-04
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
CompletedNCT04370873
Start: 2020-06-05End: 2022-01-12Updated: 2025-05-28
Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
WithdrawnNCT04425733
Start: 2020-07-07End: 2020-11-10Updated: 2025-05-15
Phase 2
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
CompletedNCT04732221
Start: 2021-05-19End: 2024-07-02Updated: 2025-05-25
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Active, not recruitingNCT05612035
Start: 2023-03-16End: 2029-10-08Updated: 2026-05-01